05/11/22 4:15 PMNasdaq : BCDA earningslow floatBioCardia Reports First Quarter 2022 Business Highlights and Financial ResultsBioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2022 and filed its quarterly report onRHEA-AIneutral
05/04/22 8:30 AMNasdaq : BCDA conferencesearningslow floatBioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022BioCardia ®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three months ended March 31, 2022 andRHEA-AIneutral
04/12/22 7:15 AMNasdaq : BCDA fda approvalcovid-19low floatBioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and DrugRHEA-AIneutral
03/29/22 4:05 PMNasdaq : BCDA earningslow floatBioCardia Reports 2021 Financial Results and Recent Business HighlightsBioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2021 and filed its annualRHEA-AIneutral
03/24/22 8:00 AMNasdaq : BCDA conferencesearningslow floatBioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2021 andRHEA-AIneutral
03/22/22 8:30 AMNasdaq : BCDA low floatBioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy ProcedureBioCardia®, Inc.RHEA-AIneutral
03/01/22 8:00 AMNasdaq : BCDA low floatBioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into CanadaBioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, the country’sRHEA-AIneutral
02/14/22 7:30 AMNasdaq : BCDA low floatBioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as DesignedBioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed itsRHEA-AIneutral
02/03/22 8:00 AMNasdaq : BCDA low floatBioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart FailureBioCardia ®, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for the CardiAMP ® Cell Therapy System for the treatment of heart failure. It is believed to be the first cardiac cell...RHEA-AIpositive
01/10/22 8:00 AMNasdaq : BCDA low floatBioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual ConferenceBioCardia ®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and respiratory diseases, today announced it will be delivering virtual presentations during twoRHEA-AIneutral